MedTrace Logo

National Register of Actionable Mutations

NCT05918666 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2098

Last updated 2026-01-30

No results posted yet for this study

Summary

The goal of this observational study is the creation of a national network of precision medicine, which allows to increase, for Italian patients suffering from solid tumors, the possibility of access to more innovative therapies and to collect retrospectively their clinical data.

For this purpose, a national register of actionable mutations in patients with solid tumors in advanced stage of disease will be created in which various individual, local and regional initiatives of genomic screening of cancer could merge.

Conditions

  • Solid Tumours in Advanced Stages

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Bayer

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Janssen, LP

    collaborator INDUSTRY

  • Takeda

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Clinical Research Technology S.r.l.

    collaborator INDUSTRY

  • Federation of Italian Cooperative Oncology Groups

    lead OTHER

Principal Investigators

  • Nicola Normanno · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori S.r.l. IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-27
Primary Completion
2026-10-27
Completion
2026-10-27

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918666 on ClinicalTrials.gov